Deciphera Pharmaceuticals (DCPH) 5 Aug 202020 Q2 Earnings call transcript

Good afternoon, everyone and welcome to the Deciphera Pharmaceuticals Second Quarter 2020 Financial Results Conference Call. Today’s call is being recorded. At this time, I would like to turn the call over to Jen Robinson, Vice President, Investor Relations. Jen?

Thank you, Michelle. for financial today results. you second discuss thank XXXX quarter and joining to us Deciphera’s Welcome I Relations at Jen Deciphera. am Robinson, Vice President, Investor provide Medical Executive Officer; afternoon financial Martin, Officer. Chief are With discuss Matt Dan Tucker Hoerter, a Sherman, Kelly, Officer; and Financial Chief Steve Chief this update and general and me President Commercial corporate Officer; to results the Chief

facts would Safe our statements statements that Litigation pursuant Reform begin, made commercialization I of like XXXX forward-looking historical we guidance. of Harbor are on preclinical we our you expectations Act any to forward-looking the conference Private Before that to this our of include reflecting QINLOCK call and call Examples make this not Provisions of during and current are statements expectations remind the beliefs the made programs, of clinical Securities for XXXX. and management

risks actual be COVID-XX, of those Forward-looking implied cannot of involve data, risks on our of that revise forward-looking filings. SEC those obligation update statements, and clinical the trials, no will to study XX-Q in that substantial call assure report from statements. include uncertainties and materially the or Such uncertainties differ we most you any cause statements our this expressed as set timing forth the on to quarterly other our forward-looking execution expectations and and could achieved. by recent made Form the impact or well potential as We assume results

Steve Deciphera. Executive turn the www.deciphera.com. available Hoerter, the to website now that, will With I be replay a over Chief Steve? will Officer President and call, on this Following of call company’s

FDA’s important States of switch today's QINLOCK ahead the new months and PDUFA quarter, to designing afternoon, date, of facing 's United the joining also Deciphera’s is us for and our Jen. people the the as pilot of fourth an second first with benefit post-imatinib program designed the an concurrent that patients. call. of under approval and for NDA The FDA’s inhibitors. in important real excellence also validation milestone the GIST that has of of part the oncology treatment announce of discovering, ORBIS, approval launch of purpose the of delivering built been treatment for developing we Line center everyone approved survival of time adjust participating patients for its always drugs medicines the three offers kinase of approximately meaningful and is in in was oncology health were the diagnosis, for international you And GIST. the approach FDA serves QINLOCK and overall and The for was approval review oncology thank Good novel reviewed came of product on focused only framework among and with Deciphera treatment was NDA drug QINLOCK authorities. FDA submission cancer. clinically of QINLOCK disease Project you, thousands review provides and a mission Thank a on to FDA review. proud priority setting for this control QINLOCK initiative

Australian initiative, a by of Administration. QINLOCK, and both this approval Therapeutic recently Health As the announced Canada we of part the by Goods

file further Agency European United a the Additionally, year. the we the fourth QINLOCK this of Medicines outside marketing as States, to of with to authorization we in access application look quarter expand to intend

received launch. Zai QINLOCK groundwork National that announced our specialty dedication FDA Finally, was one Because QINLOCK. Prior the the has partner that our commercial that of the NDA were working limited the commercial were and available ensure last diligently China network And commercially week Zai work, priority been excited accepted hard and Lab, or readiness QINLOCK approval, had of medical along affairs earlier lay their to we pharmacy to announce within through the teams NMPA has Administration for able for and Products we optimize to to the Medical review. with receiving month, NDA today, approval.

Commercial During share today, Martin, call our commercial into the Dan the our insights Officer Chief will launch. initial

that we of in to in still the progress are of the GIST the far, While launch, we very and potential the our setting. days so pleased transform early are the treatment with has believe post-imatinib QINLOCK

Phase inhibitors. across of in and Dan? novel tumor exciting our results year. for X our X Beyond discuss later Matt our continue Officer launch. the Officer in advance our QINLOCK additional study DCC-XXXX call this progress Commercial our to present Dan for the to Chief candidates, cell we've TGCT to with detail of to product first now Martin, from plans QINLOCK, our we I'll over made declare portfolio kinase our data in to including Sherman, quarter And switch pipeline discuss Chief of Phase will dose commercial our turn control further partial Medical the patients recommended giant the tenosynovial

results launch of pleased to that initial accounted just weeks. over was days approximately partial selling you, the QINLOCK on Therefore, regarding period Today well the important six insights to a May Steve. insights commercial I afternoon. approved will recall results XXth. Good quarter XX early from QINLOCK company, as as and first Thank share as a Deciphera's share I'm commercial launch. stage It's

rapid sales results key to from leaders, our Several revenue QX We was research it's product are profile and interactions million. selling result Recent need the strong QINLOCK first perceptions customer determination quarter awareness team, prescriber $X.X despite launch. positive result. net with But contributed for of market opinion very high factors for pleased first, of and demand important this feedback and that growth COVID-XX. and GIST partial believe with our QINLOCK. the QINLOCK. clinical facing the our label of triggers unmet environment a of in presented was teams focus of the demand challenging FDA advanced of QINLOCK strong we by GIST, and

prescribers In to period, launch XX% six week and more and pleased unique there of prescriber of very initial than XX this were representing XX% more were from prescribers unique we were treated trials QINLOCK Second, QINLOCK institutions. see XXX XX% no diversity. our breadth clinical our significant had Approximately treatment. institutions with And GIST where understanding of prior prescribing on patients received with experience than of participation access program. community consistent in these expanded nearly or patients QINLOCK accounts

Third, team to I am access that patient broad pleased our market rapidly access to share has QINLOCK. achieved

QINLOCK enabled to within preparations our shipment launch us of extensive days first Our patient approval. of deliver

focused Additionally, have label. with that coverage led across broad commercial of are coverage Medicare favorable consistent and to policies our both adoption payers, including payer efforts

access, from several additional results breadth benefited and factors. patient our QX In addition to strong demand, encouraging prescriber broad

our a from revenue access closed patients First, our included from access the The to upon our program switch QX contribution May in who FDA U.S. was modest of portion commercial U.S. expanded approval QINLOCK. program expanded drug in

impact within product our In to our included expect subsequent inventory addition, in specialty channel partners line as targets. we the And network oncology of with our initial distributors. build QX revenue hand pharmacies by with in quarters. was diminish launch, of and impact specialty our any this oral Inventory held inventory

XX% percentage six our lower patients our free timeframe, of was to Lastly, approximately XX%. Assistance drug Patient the launch receiving week than Program talking under estimate of initial of

receive moving we to However, quarter. this as free to to as this vary And expect previously, program. continue of can quarter we drug forward, communicated patients XX% XX% approximately percentage part to of

provide update challenges call and our expectations the navigating the like of to over turning potential Matt, I the would an regarding our experience to regarding moving forward. Coronavirus Before unprecedented pandemic, impact

strategy capabilities their worked remote As launch our hard team detailing launch investment I tactics other to includes calls, marketing This increasing deploying, model. and has the previous to in extremely developing reviewed and on non-personal adapt cross digital our virtual functional channels. and

required activities pharmacists complex accessing other institutions can stakeholders, and experience virtual while early physicians, within healthcare can that the coordinating be of be can is take challenging longer to do Our large remotely. usual effective, than so quite critical and details when and

our with GIST below prescribers patients for shift related may GIST delaying GIST treatment and due pre-COVID-XX patient levels, to Additionally, switches concerns. market consider advanced some research volume traders remains indicate COVID-XX that recent that

impact in the QINLOCK QINLOCK Matt are continued turn receive Patient uninsured the of to with Program. while be patient GIST millions initial for to on proportion pleased to of spread drug programs. now it remains term. to related eligible the our impacts will -- people GIST access, we Matt? free treatment have uptake to I position losses progress discuss due COVID-XX pandemic Assistance with job our who response the near newly clinical Therefore, rate of patients the triggers of what over very to are to will under Lastly, of ongoing the seen call and

GIST and medicines benefit stage Thank we've fourth our remained our Dicephera enters our ongoing understanding for additional initial company, line patients of create unmet a into commercial you, with new Dan. committed programs broadening to needs. deeply medical approval significant to as transition patients beyond Whereas such clinical advancing stage

a team plan line second beyond lifecycle team the support as INVICTUS The survival, to safety or as along Lancet in in PFS with progression meaningful it's robust with launch, to patients. potential treat survival a the and from management In and June, highlighting compared free well-tolerated were includes potential publication well commercial Oncology study GIST QINLOCK results our successful pivotal published executes strategy, placebo, medical QINLOCK While and which continues profile. the overall our improvement in of significant clinically to GIST a improvement

the in Phase [indiscernible] look XXXX ongoing the INVICTUS QINLOCK Virtual demonstrating presenting important XXth study, the presentation. patient additional World of on program ASCO Gastrointestinal study and Cancer outcome July. to clinical in the studies Congress We of at forward Virtual Scientific September, ESMO additional crossover also from benefit ESMO presented QINLOCK we additional and positive data May results the Congress from data at patients pivotal for X upcoming reported At

study QINLOCK phases dose were [Indiscernible]. intra-patient the and in escalation dose in line progression survival dose The milligrams treatment, Patients GIST had XXX BID. to who first patients presentation milligrams received the escalation, titled enrolled fourth stromal second, X in This QD. progression option is who and disease meaningful gastrointestinal free escalated XXX expansion tumor be presentation clinically following Phase to focuses across the ripretinib third provides on

the We will report and dose from PFS-X Progression escalation initial date dose or disease Survival progression or subsequent subgroup BID. Free of PFS-X escalated the Progression patients XXX to of at this Free the milligrams who Survival to from or the meeting death second

and the with patients The update advanced This second or treatment with X GIST greater safety which months line survival central from as XXXX, updated presentation data Phase independence blinded INVICTUS PFS presented ESMO year. titled, highlight with up presentation benefit will from overall Clinical study. cut-off the at of last by is March fourth data nine a and X, is additional follow an new review, ripretinib of

for the multiple to treatment patients the alter encouraged Deciphera meaningfully to for lines continues Our team across at of landscape therapy. be of QINLOCK the by potential spectrum

to Line X XX-countries that study GIST physicians, also we the track and year QINLOCK fourth treatment ripretinib by that the While fourth that with for where been have complete quarter GIST, activated benefit. received there has patients the pleased report in patients of we of on QINLOCK to To patients standard the the advancing Line QINLOCK, meaningful been enrollment with and Phase GIST. are well study. INTRIGUE of we are look we could are in that current forward XXX in of end, this treating ongoing Xnd the Currently today second provide to to target in believe our line the compared sites

rapidly also next our control to wave kinase of inhibitors. We novel switch continue advance

dose to DCC-XXXX, giant initiate tumor TGCT our X of collected turning year. opponent select and we First on track the inhibitor, the for tenosynovial Phase this in cell to CSFXR, are or expansion level selective treatment

to from fourth escalation study present I quarter. the Phase the the expect dose portion patients initial We at data Medical from meeting in of

initial later proof-of-concept year. forward at As you last additional presented data Society data Annual sharing or patients Patient Connected And clinical year. to three we recall, the CPOS we TGCT Oncology Meeting in look this

potent our selective in Rebastinib, inhibitor. TIEX to Turning

XX%, preliminary were We Xb/X two with encouraged Carboplatin. in the studies the phase ASCO one with an objective data May, cancer cohort endometrial ongoing in at study, and clinical rate the at chemotherapy, which by paclitaxel and are highly at eight conducting XXXX X we At with rate response XX% from the one showed Part clinical meeting benefit presented Paclitaxel of of weeks. combination Virtual the

second forward ovarian we As the have than the from data we presentation Congress at now of to the responses Two-stage four the the of has study the cohort cancer stage which the advanced earnings look cohort, in Part We presenting design. announced quarter, Simon last September. more observed poster from in to during also ovarian X ESMO Virtual in our cancer

Carboplatin the happy of part we presenting to combination that addition, at will We're on in potential IND mutant rebastinib In treat also confirm file with today, Autophagy an in our that of one announced the ESMO be study Congress. data cancers fourth RAS designed this first for we of from the XXXX, to quarter class in year. Inhibitor, we are track Virtual to

Finally, ongoing COVID-XX say few to words on I pandemic. wanted a the

Our a moment appropriate as patients well studies as to remain open and Drug Investigational for follow. continue receive

We with and Tucker to are now the sites call regulatory studies contract Chief committed will consistent to research our Kelly, supporting in turn patients over our receive results. help Officer review to clinical ensure manner a financial I to safe care guidance. Financial Tucker? the organizations

million pharmacy first product our were Total continue approximately QINLOCK can like May sales net collaboration second The to which to revenue to quarter rate for be product net Please FDA million quarter and approval. of prior to specialty quarter product than the our revenues adjustment in million, $X.X includes of and keep product upon vary recognized second of slightly growth partial quarter, from in I'd of second to to Matt. of QINLOCK our revenue net $X.X results, expect from quarter our gross QX net we Thanks, guidance. shipments includes which of delivery was lower going the We financial and the mind partners, the net includes sales. review and highlights distribution quarter forward. following $X.X XX% sales XXXX revenue. our the in to QINLOCK first

due was upon of under we a Cost a tumor. Zai submission was with Medical ended in for the to for immaterial. the three In administration their Products million drug XXXX new June advanced payment addition, our application adult $X of sales $X.X milestone collaboration recognized China for National of XX, the including million gastrointestinal months ripretinib, Lab, agreement stromal revenue patients treatment

the depleted, not were be and costs second manufactured recorded cost majority approval, excluding and significant inventory XXXX. in XXXX, to prior which consistent expenses quarter QINLOCK to sold. until of R&D of were thus with our sales initial the will of sales incurred $XX.X As of and additional the expenses of million inventory operating of first is the quarter were expense. In Cost the as related is million, the manufacturing pre-launch total $XX remain FDA quarter sales second

As development the across commercial expenses selling second were XXXX. of general approximately we the $XX.X clinical as as development $XX.X activities QINLOCK, support approximately pipeline. Research well and quarter and administrative our were launch advance for of expenses the million million and

to expect We we clinical which now expect position half as QINLOCK. half a We with financial be control will fund second well that, QINLOCK $XXX to the of of commercial pipeline of XXXX. cash, quarter the ended operating our to ended the half operations the U.S. the in launch to and second execute in of year, our inhibitors. novel our expenses will Steve. development cash second exciting capitalized strong first this of increase fund we to our launch approximately support of quarter the the With the call remain and in continue of year the development and compared and into over million, back second securities the I'll turn to marketable the of switch pipeline equivalents We sufficient of

you, Thank Tucker.

work Before quarter. over thank we for hard their entire and for call I'd and this here the team to impressive the focus take a like open at Deciphera Q&A, moment past

to that open and promising confident that our execute launch, the reported QINLOCK I'd like Looking together positioned development partial of on successfully the momentum are we forward, first I'm questions. programs. quarter our our operator, to building for to call commercial in we remaining well of today, With continue both launch

from of question Sandler. [Operator line the Piper you. your Raymond from instructions] Chris Thank And first

now Your open. line is

taking Thanks number of the on the out Congrats great the for gate. right question.

that couple think I a Just heard guys heard the you I stocking, I I questions, you on QINLOCK quantify of say number revenue some don't but that think was that.

demand? sense end of kind So, just provide you could us of some user I'm curious if

Chris. Sure,

So, this is Steve.

So that. to I'd take be happy

pleased out launch quarter and gate. reported yeah the partial of of revenues initial So, that today we've we're really the this strong with

may able in on did the hear, demand which, customary But in we build of inventory mentioned been usual of saw note remarks, this the technical we there. quarter been partial know his contributing I you factors, addition in the there to have issues Dan one line was strong to which have that some prepared that and As first launch.

inventory. in we with for So, quantified but terms on said hand ended that we haven't we expected to days that see have quarter we what the of

maybe here. question and another Okay, just

I in think XX% I you have slides prescribers of think guys academic that been community XX% sort heard community. I've of of mix were prescribers between seen mentioned academic the and described I XX% and the previous community has you But way based.

A, the But guess, guess I even to So, that would given more community? is are guys one line, to second that, you is, there's and a in academic? on I that that maybe that getting surprise some earlier sense the especially is part fourth you maybe label that I of towards skewed an a mean, a use expect be lines

Yeah. question. Thanks, great That's a Chris.

take ask Dan of questions to I'll both So, those for Martin, you.

I audio? able hear and the okay? All Yeah, hope How's you're me to right.

Okay?

Yes.

any previously. So, audio for apologies challenges

question XX% treatment clarify versus about of the previously part So, XX% in we so, overall, community academic is just happens that the GIST of the setting. in what said community, academic setting, about to your first

go as treatment you Now line line, you the to fourth the therapy setting. bit and dwindle, when expect, switches might referrals options in academic of as your that at patient's in the later point, more you you a look get

setting. community thought anywhere to fourth GIST always of XX% from the XX% in still was probably in we've happening line However, treatment the

about my was volume and XX% can you guess. treated per do a coming consistent bit of QINLOCK patient is community, which one would prescriber that, shared math the what setting, of remarks the the patient's the prepared that in about academic from heavier with prescribers the our in little is XX% so And it's just we

consistent way expected. So, the second first part of what a We're your earlier the question, partial we to with really good question. gone. therapy. with really your It's lines quarter pretty of With regard has pleased

is an Of of are with launch fourth course, our efforts, of That who receiving interest so indication. in approved lines lines, recognized consistent are and in the be all of are all of FDA the therapy. very physicians optimizing the a may may on really available reliable some line patients, sources of materials, have our treatment in etcetera, our imperfect, our earlier to promotional in that proportion or all earlier of estimate using that QINLOCK QINLOCK challenging all the clear we said, provide picture. It's often focus data don't that

So, at off any, us launch, label. how if really still determine much use early on it's this very to I'm time, was difficult for

Okay, very much. thanks

Thank you.

Your next question from Eun the is Jefferies. line from of Yang

Your line open. is now

Thanks much. very

ask you to So, again I about sales. second the just want quarter

So, you the consensus And then X.X. came million. less was at than a

So, talk sales how can benefited a they expanded do well about patient your to as, from the you inventory commercial? actually much switching as of

Yes, Eun, here. it's Steve

in some So, of that strong prepared first the that color could contributed performance factors partial you provide this but more in a Dan maybe his little Dan remarks, terms of covered in bit quarter. with Eun to

Steve. Thanks, Good absolutely. Yeah, question.

I importantly, very primarily, think. demand that's really a broad those result and primary and There really So, number the diversity. patient toward drivers. to I access again, encouraging reiterate factors rapid for it's gains that. strong prescriber think QINLOCK also physician were initial contributed are that strong our we to And so of important, want breadth

that of some patients in color. revenue prepared our from Additionally, provide Access to additional We conversion Expanded QX was contribution commercial some the just remarks to outlined Program product. U.S. from to there my

an that, partial details some closed, to for FDA have revenues is as inventory inventory oncology specific program our any given is on can build, U.S. say what now we it upon in typical it's tied oral that to not in initial can build. our contribution I first share to typical have relates then of approval. launch And as is is quarter EAP. What the We

great inventory However, quarters. to job teams to was that the very held the And impact the our in the by in did our a hand diminish expect quarter. on mentioned partners targets. managing his prior inventory throughout contribution with And subsequent channel initial build or consistent the inventory as we of answer days Steve a would question,

lines And you all you. in Thank have Line? usage QINLOCK your fourth than seen -- actually lines your all

that Yeah, would to address question? like Dan, you

know an mentioned certainly interest, I we of my area Sure, as is question, to in this the to the answer question. but prior prior

we QINLOCK all on imperfect are therapy. using in this launch data clear earlier that. focused that fourth promotional of it's earlier don't interest foremost, The toward may We’ve to our are to estimate, picture. a some of patients may of First early reliable proportion are do because recognized have be treatment lines Line efforts physicians in the and on fact remains receiving challenging launch in if or and what provide the any, and especially often just lines, sources and

time, difficult in if of So us this is to much at determine any, use just earlier therapy. how for lines

past you Okay. have so in cohort. driven the expansion a I at other solid question, key in tumors, the And looking repetitive are tumors last

So you types any of pursue? may on what is update there tumors

Yeah, Eun the for thanks it’s Steve, question.

up in accepted oral at remarks referenced coming his mini pleased X Matt ESMO. Phase presentation really data we’re of as be to see some a that the So prepared

Phase So the from this the cohorts GIST X. is

call. had part this that a As update of the don't number you cohorts, further Phase signal we expansion noted, have there time seeking other we on And are of you today's a cohorts X. at as for

you. Thank

of the from Next line from question Lawson Barclays. Peter

Your line open. is now

for taking thanks Hi, my questions.

about XQ. mean, see expect the we thinking TGCT metrics be should data that data? on patients, we a I any Just of number to for in should what

hey Steve. Peter, Yeah, it's

some color that. add off So please free maybe additional to I'll then and start feel Matt, to that answering

noted year. XXXX the program a up his balance as milestones, Matt coming milestones remarks, couple the we have important the of of for prepared in So for

a of those two recommended dose. declare is to phase One

Matt noted, the medical the quarter an in year. the at expansion is other we of meeting in And provide coming Phase data to a up from then also fourth to open patients The X cohort with as intend TGCT.

that can I to we patients number a see data guided on. haven't think, So to of expect specifically you

that last the As had proof of you initial three first clinical year, at reported we’ve we patients know, CTOS concept treated. in

the we'll what of be at to patients. to number expect. us specify have But, going go course, on of and, to the forward? optimal tuned what tough what course, with we're looking dose as data that of from the updates to time and we is for data an for data Peter. But this agent for year. more So going data is patients How the early approved pexidartinib end those we some this the additional for disease through exactly what of other compare does accumulate see the stay at for TGCT, come Thanks, so

how much. so on And see you Mastocytosis? for the Systemic things thoughts moving update just around ASM any just and we updated thank could then, data, are when next Okay, an

Sure.

So to I'm that. address happy

the I GIST similar, to from ESMO in X. Matt at Eun’s the noted Phase we question, somewhat his cohorts So think, expansion that earlier. have prepared data from remarks will

that escalated we're going patients So time, for subset study. dose on be first XXX to BID reporting that to the the of in

free escalation, then So for patients. PFS be PFS X. then progression the reporting survival X, of those we'll the interval initial And so we captured upon on dose

that So also we'll subset, X the PFS report data. then for

I X. of call from update other today's Phase don't on the have in expansion further any So, cohorts terms the

questions. the much. so Thanks taking thank for Okay, you

you. Thank

Your Smith next question Michael of from the Guggenheim. from line

now Your line open. is

Maybe is specify degree me. could for have doesn't A dynamics broad from that some and be to to bucket. guys, a with the in a QINLOCK wondering second certain PDGFRα benefits dynamics well you the with competitive overlap I how my of obviously and thanks you was as if there? that QINLOCK a taking quarter evolving around congrats what comment been label competitive questions positive for question on, the Hey, see genotype, obviously patients and just you but from just in on there the might do terms see launch treated

Michael. thanks Yeah,

and in we've back number So then market second what a the in gastrointestinal JP treatment done. we've over seen off that INVICTUS research getting heard stromal bit. we've that starting in the turn it can the based to with what that conference the it's profile comment the randomized also those months at in tumor. But who with for target consistently And well, Morgan quarter options up Steve, they of and evaluate from and we've product very to the profile, probably we've of as We've maybe a tee what patients. spectrum I'll for data talked as that January extensive is on their the reactions a just maybe physicians Dan about start little with to done research patients seen data on market now, broad

clinically as is the all of really the free But overall mutational well such So a drug what very irrespective fact based status, that tolerated also meaningful the survival. striking benefit the that physicians And data. we in on that have B, against in INVICTUS, of a terms randomized improvement of drug. value, backdrop A, fact offers that we of progression survival and

data So based best or our in to be data. class the that expectation the disease INVICTUS based is potential ripretinib on QINLOCK really the this has for on

recently them about on Now, data hearing agent label, what has terms context. maybe of want the part means comment further a patients ago months But, for what of you puts a seeing disease? exon approved VOYAGER this that in the physicians where in INVICTUS other avapritinib with out, narrow we're options XX one a of and think Dan, internalizing and to that what point patients they with from that you subset of as certainly driven for couple XX out, in trial point reported competitive disease, for you are as exon out there's the negative marketplace driven I that as now think the is

Sure.

the relates thing Steve’s Just that a I profiles. couple answer of I mean, it thoughts on the both to add as only of question, the would parts to

narrow and just is were been now profile, very other very, We that for traders QINLOCK QINLOCK increasingly are and the continue positives in is one strong to. that back this including And, consistently understanding launched we've research just things products is doing differentiated what as much to pointed do I've been how see to comes the research of space, more profile. that pleased from GIST avapritinib’s Steve

the As broad indication. to of one it relates a really have fortunate PDGFRα, we're to things is that very

it’s that of And going collect so – commerce policies to for payer don’t of so and patients, treated really us we track reason we’re into QINLOCK all profile data or seeing no are drug. agonistic there’s the place, on because the to mutation they mutation not

it's So type potentially mutation standard including always inclusive Steve types, best in that QINLOCK care And mentioned matter. patients all for wild post-imatinib the class in viewed setting. we've as of that and product of of

And you studies? of cohort? in confidence just expansion here here? be randomized bar Maybe question Do Thanks. Okay, we I think would was talked should what here TGCT? maybe level market dose thoughts a Should you win XB this term arm update DCC-XXXX, development some about to path pexidartinib path on efficacy need a in And X could controlled I Phase you on to how high guess we year. Or single Phase the longer then potential approval on strategy what term? based the exceed think for level regulatory just the example? the example, wondering that later great. you know a get about the for forward about I longer

Thanks, Yeah. Michael.

good you that's like So that? take question. Matt, a to would

Matt. just Yeah. There passing some storm is I and audio earlier sure Thanks, coming is you trouble to Okay, with hear Steve this the was Sure. through overhead. Can clearly. Michael. Thanks, the make me? want

very very, question. good it's So

TGCT at we the we'll about year, end start in meeting update year this the me be folks further the for patients ongoing Let initiation we in able said, talk to the updates as of just of an in the to medical X at of dose, the recommended Phase study. forward X the look data and with saying, expansion cohort, to Phase also quarter fourth a this

for REMS a program So to the we XX% use XX% further significant full randomized FDA. profile the in to patient we and rate response patient conducted XXX development August objective receive blackbox on think as treatment. if to warning based on every placebo. the a time, about development, with one-to-one having at despite were for can on it requirement approved approval, last also when a year, they enrollment by label able the was benchmark of that study a pretty XX% pexidartinib safety And And

drug noted that patients. It So, using we on on at should a for for EU. pexidartinibin opinion CHMP preapproval that in safer potentially the development as the had benchmark also think a XXXX sort negative has be ability TGCT that the of

speaks again, safety that So to pexi. the was with shown the profile

thanks questions my taking and the for Well, launch again. great. congrats on Okay,

Yeah, thanks, Michael.

you. Thank

the of Your SunTrust. next from question Karnauskas, Robyn line

now line open. Your is

for for Robyn, is this our questions. on Hi, Securities. SunTrust taking Nicole Thanks

is overlap patients not the missed you remind & filled many if Can how in PDGFRα And quickly, drug what received the or in also, mutants what’s ripretinib So I'm sunitinib? this, many quarter? then and KIT were us the between sure how in prescriptions and profile but second I

question. for Steve. Nicole it's Hi, Yeah. the Thanks

for of published example take of patients, metrics maybe sharing and in number So cancer we But relative ask scripts call. then of the that we disclosed very I'll believe to as first, ripretinib not on indicator breadth we're far. in launch in of the That's very for year. importantly, cell, so question it’s following sunitinib But the up be prepared certainly specifically externally one the closely. spectrum the the which And pleased of and that the what like drug second about the that and he'd said very pleased number far, academic question we're we're a a and in strong outline real response of I'll of not of only last in the utilization launch. with see a very this Matt, very, being we'll previously setting, his setting so but reflection physicians spans quarterly remarks, activity the treated patients to basis. we've if just demand, on It's that to on questions today's haven't community then briefly Dan have also based so come to use

to So you take first question? Matt, do want that

Sure.

line to yeah, setting line. So approved second about for the is data compared the historical ripretinib the for second the as the now is activity question so I speaking which sunitinib, in understand of

third present at year, last fourth in the second line triple the line, XXX looked from where Phase X did So, data across meeting patients. line we we patients and study the

objective had pivotal response sunitinib second XX% had survival study we its a study rate. on down so, survival progression response study of in free a And month the with with And objective line in about patients, while comparison, a a progression months that XX.X going rate. X.X X% it's free across

us a that gave INTRIGUE study. So the reason to for believe initiating

that too, you study sunitinib. As intent we X study comparing know highlighted by of the of this our reprinted today our end year. And enrollment the INTRIGUE as as study completing is Phase is well to randomized

thanks much. Great, Okay. so

you. Thank

line question from from of the Benjamin next JMP Ren securities. Your

line is open. Your

the a first congratulations Thanks a good in of sort those great to based and got Hey, my ex-U.S. approvals having kind of in with bit Maybe afternoon taking See, of kind for broad launch. start you've distributor questions a the several on strategy. do little delivery to guys. question countries.

think how NDA from kind your timing on may just latest contributing You and take being P&L have accepted. when through China Can your see thoughts the the start revenues now launch you these the of how you you to that us unfolding? of ex-U.S.

Yeah, the for Steve. Thanks Ren question. it's

but broke gist the any up I question a and revenues. strategy think ex-U.S. little in for bit, timing the got future of You I terms of potential

further we physicians get are here of looking in brand continuing about we to maybe about talk here days we in about just the of strategy. or globally of regulatory launch and QINLOCK first, of in excited educate U.S. strokes can our and as broad out the the approved kind U.S. terms to So utilization early ripretinib drive Obviously forward the where the

As part Project Australia. in of we've course in and noted previously, ORBIS. was This we have approval now of Canada

physicians know a be pricing previously, specifically talked retain with Ren, local the the likely products and to for two territories and with data partner Australia a reimbursement strategy support we territories very approach, and both those then as a about reimbursement lengthy help we've get Both distributor that's And our and in of engage to rights course but also process. As is be physically to product to where we you to able pricing product. and those distributor navigate share of physicians the the and patients with somewhat the process. can Canada, there

these other of that very and then educating product a and a getting what and price we of where from in quite that are launch done here in different markets, insurance we HTA bit then negotiation U.S. to are payer But price course, of approval. be in working So experienced single work it has there's with companies. submitting to bodies territories the a these data immediately,

see are we territories. certainly revenues project those difficult to Ren, now from future. some at point So we when where in It's might off from further the

respect China. with Now to

As the receive this as anticipate we they noted Zai today, who disclose and they partner by we the they our is application for review months. approval that discussed today, could morning. a potential as priority be Lab, And China, submitted believe Greater for timeline about they XX

there the was Unlike [Indiscernible]. prescribed with the by think NMPA take here action a action experience I the that application. date the to time which their system in U.S., has isn't on

commercializing able Zai So in can would be there take then And they terms lock when specifically. is start some then when as to China may of in action. course, of uncertainty

going press Medicines we'll Matt is making filing noted, application we to say our refined the four. also next be And that quarter further release, to European as in today the the filing authorization noted regulatory guidance significant Now, milestone we be for us Agency. marketing the and that in to

Europe. go-to-market to So is be of things the one strategy yet is going our we what for haven't disclosed

filing is we approach right for so, as European what to to the our And time disclose at get that going exactly go-to-market and then Union. be will the closer

the it. color be give should very XXXX. tumors model be And we this just how be share? us could But a you of I bit know That's little be this going or thinking [Technical we sort you'll IND. gears maybe about thinking can maybe asset forward? helpful. filing focusing the particular of on asset then should color just Difficulty] and Got switching development you Should to on any about more how we

Sure.

maybe So I'll to then Matt. it over and I'll start turn off

is next So, Matt know, maybe know that about for some in which RAS we pathway, IND cancers. program, XXXX? the first as we want an we're autophagy the end before of you out you're of an making the excited program mutant offer it class how plan This year XXXX. is really And to potential viewing research file the our for escape coming ULK organization. color inhibitor pathway on path you targeting development potential to the for But additional our

Thanks, Steve.

represent opportunity to mutant path development the would this, ULK are autophagy. as in The yeah, of so of inhibitor So, be XXXX indicated today, first indicated in develop we as about inhibitor, we the cancer targeted as very concerning XX% human intractable as we as excited RAS class of therapies, additional cancers are particularly patients colorectal proximately RAS well by significant cancer. all cancers, Mutant and patients with cancer fairly pancreatic cancers of cancers. and of with the many in number lung represented

the we if be the we would once development, And along sharing look once move think So, we've details further forward you more there indications. -- IND further with about filing. to potentially those

Perfect, and thanks questions congratulations. the for taking

Yeah, thanks, Reni.

you. Thank

is line next Andrew Behrens question from the your from So, SVB Leerink.

Your line is now open.

quarter. Congrats for thanks. the Hi, the on results

some you to if have I failed not getting I a addressed was power wondering back-in. already patients topics of outage the had a or are wanted dial guys you ask not get So, if whether but with I that also [Indiscernible] you're gotten then drug? awaiting that GIST warehouse patients a yet. just of color a to were novel on sutin, And seeing

got Thanks, you you'd Yeah. address good Andy, really I'll questions. if Dan like to both Martin, ask those?

Andy. Appreciate absolutely. Thanks, Yes, the questions.

about was question first So, patient. one earlier

are on laser launch line. promoting So, focused, in optimizing the we and of drug the fourth course

using some some lines said, do appreciate our have and physicians being materials therapy. who messaging course, may That fourth label all indication. line efforts may So, on of the we of are, and earlier interest that and there marking in of and be whatnot

don't However, in or just available, picture. the is source proportion clear data estimate a it's often imperfect lines. provide earlier be really The treatment to of patients challenging who and may reliable receiving they're

us So, if it's use off time, difficult label. it's still how certainly to this early for any, much at days is determine and

sort Regarding or not bolus of your about was whether question prevalent a patients. there of

some sick Another how early quite of again, in What and early experience good marketplace, of line frankly, diversity days, the late we patients communicated prescriber there these we say is demand not QINLOCK be with and how significant prevalent is, the we've the setting previously to would that of in did expect this patients given to assess. bolus setting, thrilled are? prescribers. tough that question, are And the being of breadth I a

I U.S. the QX did you've that. given that conversion commercial pleased drug. impact One revenue. other was power outage mentioned of the with it to our patients Program a heard our And really So, modest Access a know couple also to also, factors did mention in don't before, but of contributed we we if Expanded experience,

a then, Patient inventory anticipated inventory Another -- oncology with initial of a And than build. particularly quarter of inventory so with first utilization Assistance thirdly, partial build, oral initial impact was any lower consistent one launch, our Program.

that, have we estimated to forward. We moving in previously but hold continue that than XX% XX% lower to to expect true estimate bit came

you they are Okay, answer present appreciate presented data on that asked then I call, the to color I still that? SM really that, Peter I by the end? think planning wasn't and you said on Are you clear all about guys the QX your on year

question, Thanks Thanks. for Sure. Andy. the

some to X. noted Peter’s data is response I in from have question Phase the that my what So, we

cohorts noted, the accepted GIST presentation oral a mini at has ESMO. from been as As Matt that

for this at looking PFS X, So, X that escalated XXX BID to as dose who and the looking as patient's is cohort. PFS at well

cohorts we call any from with the today's Phase on So, don't other respect to X. update further have

enrolling that the SM status it? cohorts or of one Is of Okay. still

at we this have update on further don't Yeah, time any cohort. the

As us to previously, about, cohort talked been a we've has challenging really this that for has been enroll.

to from a tough been BID. the talked protocol at how it's start patients about to you we As us. we But had year, know, going for XXX last amended treat

at for you any that update on this time have we -- cohort. So, don't further any

the for thanks right, appreciate All questions, congrats again. Okay. and

Andy. you. Thanks, Thank

you. Thank

the from line question from next Ben [Indiscernible] Cannacord. of Your

open. is now Your line

remarked that taking Hi. I'm these of hard Thanks if be with rank you launch out see out launch up maybe for the there for of some my formats agree if the getting And companies headwinds you for virtual get just meetings that and you the trajectory has some company word the like going? product wondering A the of order, made could it quarter. might and that congratulations challenges question medical on that, couple launches. have might Thanks. towards to and this of ASCO

but been And to share We Yeah. call. in He some discussion of some Thanks, we're COVID-XX so in prepared talking Dan be may Dan? additional engage in in what the what that now color. potential we're launch, a of the I'm course COVID-XX? the given terms great terms remarks, with question. the the middle It's good on offer about had in physicians a QX of in would position started be Ben. impact the has of being promotional seeing, sure of our ahead able he and can experience additional some color far challenges what a to

Sure, absolutely.

but virtual facility longer one-off in be As it can that coordinate you're walk bit engagements, spend can't not day it is and frankly, with it coordinate you challenging. all thing. that it remotely can can normal. can often are be can one the in of we and sometimes it done, in But a have live other effective. far when the us what it details you're The be to is pharmacists And can activities than healthcare when it's so be, take that to trying is the to details, via virtual challenge that relates institutions, stakeholders these told doing able complex has to physicians, experience they diverse key large of and stakeholders our when virtual many very

again, to trajectory, prescribers physician, -- the all FDA label. something to as the with pleased I ramp reaction to that we've GIST relates profile to to really to underscore But, the mind keep for been consideration how just of QINLOCK, the it's sort it So, we've want thing. into in data been

and does volume to we've with some some prepared asked And means. moving them some that questions is I late the pre result would effective volume moving as prescribers someone that. virtual patient when impact result the we switches are right create of about the below as research GIST line expectations front still market to some overall COVID, physicians been beyond and of in consider So, able a levels. pointed of done COVID patient a or we've it's the related of extensive somewhat challenges and that forward, folks for that of just GIST launch COVID-XX a very that remarks get COVID of means, via forward It delaying in have even noted concerns. some COVID

So, those it got on are and some our of the things monitor as relates challenges. continue eye we'll COVID-XX we've to to that

of actually tackling Can until of Is those. of to you R&D amount be quick luck coming cost incurring that in goods? of wish out inventory just you on or comment from that where it's have I great, to I into the going two. flowed follow-up Okay, prior the start you prepaid going another approval? best forward

initial the before can products goods, the of take we rate given expense would R&D. materials I the see so the on for Up then time are you'll we we some Once a use all will it right, some quite an approval, normalized of more balance That's we cost start expense capitalization start higher and inventory to through sheet commercial of that reached until that prior that one. have now, but capitalize approval, to time to of be approval.

Okay.

financial to I China? the in approval to you for refresh have think would remarked remind take tricky forward. Can last milestones about going Zai is, could us be approval I and thereafter? modeling you item upon months as question it that, long it's just what be as So get and And going XX

like Yeah Tucker, -- would you take want to that to you question?

Sure.

breakdown might specifically and We've milestone based for a itself a individual a obviously in approval announce quarter, milestones. provided given second commercial today what aggregate which be. that did on the specifics for we the haven't we $X milestone but We million has haven't future recognized So commercial milestones. development filing the about a of talked we these payment, the

much. good you luck Okay, Thanks fair to guys. very And enough.

Thank you.

you. Thank

question the next Yang from Your line Jefferies. from Eun of

is now line Your open.

the question. for you follow-up Thank

that any I in INTRIGUE timeline fourth the for the primary for to you line with ask missed in quarter, expectation June at So the do date for expectation? is you. Looking ClinicalTrials.gov want your study patient so enrollment of Thank XXXX, the completion still X you just Phase you have still data? completion

Eun, for the Steve. Thanks it’s Hi, question. Yeah.

first that the to you of time of completion June what study that right, reference when up ClinicalTrials.gov we You're had study on up. XXXX ClinicalTrials.gov we was in loaded put

with in that, pace enrollment we're what So with provide We're is year. we'll noted site we Matt of the that of additional data end enrollment. color the when then that And intend study as the said, course we've milestone complete we pleased openings we and pleased prepared enrollment, achieve some the remarks his at to, the getting to from on to of seen to target in might we of when see the study. expect

think us read information a the read give for on a additional will we'll could I be what that better timeline out. have

Of event to study, analysis in that's course, endpoint endpoint. an it's to in the the PFS time

the update end of provide to to So by accumulate year. in you the course completion get we have pace But and events the overtime based of to on the target part enrollment wait, of here for the like. we'll of enrollment that when

you. Thank

And questions the have further any we don't over phone.

Let back me call to turn over Steve.

today of care. a QINLOCK our Thanks you. balance Great. continued support. programs. Michelle for joining Take thanks thank on commercial you all for updated We call launch well of have with our you and you everybody us to first Hope all keeping progress as the great on our Thank to forward continued the your as of evening. look development and

Ladies Thank for conference this you today's concludes joining. call. and gentlemen,

disconnect. now may You